TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01680809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression stocking 15-20mmHg
Description: Compression stocking with 15-20mmHg of compression

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression stocking 20-30mmHg
Description: Compression stocking with 20-30mmHg of compression
Study: NCT02576977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200 mg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: pomalidomide 4 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: pomalidomide 4 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone 40 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 40 mg tablets
Study: NCT00762034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Induction therapy 500 milligram per meter squared (mg/m\^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Maintenance therapy 500 mg/m\^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Induction therapy 200 mg/m\^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.
Study: NCT01956188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA and DHA supplementation
Description: Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given 3g/d of soy oil - 5 capsules per day.
Study: NCT05643989

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stoma formation
Description: Trocar placement: the optical trocar (10 mm) will be inserted just near umbilicus . An abdominal revision is performed to determine the location of the tumor. Colon in 10 sm proximally to tumor is prepared for the discharge stoma formation. In the corresponding location on the anterior abdominal wall is formed incision of skin and subcutaneous tissue to the aponeurosis, the cut length is 2.5 sm. After that, aponeurosis crucial incision is performed. The previously prepared colon is brought out to the anterior abdominal wall with the help of a grasper. Discharge stoma is attached to a holding device; colon is fixed by the interrupted sutures (Polysorb 3-0). In the operating room, the stoma is opened, the intestinal patency is checked in both directions, and hemostasis is revealed. With the help of optics, the presence of intestinal tension is checked; if necessary, the colon is additionally mobilized.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic self-expandable metal stent placement
Description: The colonoscope is passed to the distal edge of the tumor and a biopsy of the tumor is performed (if the tumor has not previously been verified). Through the tumor stenosis radioscopically guided metal conductor with atraumatic distal end installs in the proximal colon. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis. Radioscopically and endoscopically guided disclosure of a SEMS is performed immediately after which there is an abundant discharge of gases and intestinal contents. Upon completion of the procedure, the patient is transferred to the patient's room. The next day, a control X-ray of the abdomen is taken.
Study: NCT04530838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: 20-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: 20-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13-valent pneumococcal conjugate vaccine
Study: NCT02762097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: polypectomy
Description: . During the second visit after she consents to removal of polyp revealed on prior saline sonography, a dilatation and curettage would be performed under ultrasound guidance and after successful removal of polyp (polypectomy) saline sonography would be repeated to ensure completeness of removal.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline sonography
Description: saline infusion sonography (SIS) on 8th to 11th day of menstrual cycle. On the day of admission SIS will be performed in an outpatient setting .Taking all aseptic measures a speculum will be inserted vaginally and up to 20 ml of sterile saline solution will be infused into the uterine cavity through a cervical foley's catheter of 5 french to distend the endometrial cavity. A transvaginal transducer will be used to scan the uterine cavity. In case the patient has polyps she would be offered removal under general anaesthesia on a subsequent visit as a day case procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: saline sonography
Description: saline infusion sonography (SIS) on 8th to 11th day of menstrual cycle. On the day of admission SIS will be performed in an outpatient setting .Taking all aseptic measures a speculum will be inserted vaginally and up to 20 ml of sterile saline solution will be infused into the uterine cavity through a cervical foley's catheter of 5 french to distend the endometrial cavity. A transvaginal transducer will be used to scan the uterine cavity. In case the patient has polyps she would be offered removal under general anaesthesia on a subsequent visit as a day case procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal saline would be injected into uterine cavity to delineate defects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Normal saline would be injected into uterine cavity to delineate defects
Study: NCT05744609

Intervention type: OTHER
Intervention: exposures of interest: epidemiological data, clinical characteristics, laboratory data, and chest radiographic reports
Description: epidemiological data (e.g., age, sex, and residential area), clinical characteristics (e.g., fever, cough, and wheeze), laboratory data (e.g., white blood cell, c-reaction protein, and procalcitonin), and chest radiographic reports (e.g., X-ray, CT, and ultrasound)
Study: NCT03020602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubidecarenone Injectable Nanosuspension
Description: Given IV
Study: NCT04407819

Intervention type: RADIATION
Intervention: WHOLE BODY DXA
Description: Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)

Intervention type: RADIATION
Intervention: WHOLE BODY DXA
Description: Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
Study: NCT02927847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM Nicotine Research Cigarettes (.03 mg)
Description: For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPECTRUM Nicotine Research Cigarettes (.03 mg)
Description: For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Participants in the BA+VLNC group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of behavioral activation treatment. BA components will include activity monitoring, values assessment, activity scheduling, and social contracts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling
Description: Participants in the VLNC Only group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of supportive counseling and health education. Supportive counseling and health education will include empathic listening as well as informational content on topics of exercise, nutrition, sleep and relaxation.
Study: NCT02059993

Intervention type: DEVICE
Group type: OTHER
Intervention: continuous positive airway pressure
Description: mean continuous positive airway pressure use was at least 4 hours per night;continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
Study: NCT00463801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study: NCT04813250

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ventilation mode setting
Description: Ventilation strategies with 4 kinds of ventilator mode since weaning cardiopulmonary bypass (CPB), Four group were control EtCO2 between 35～45mmHg by adjusting respiratory rate, EIT Measurements were performed under supine position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilation mode setting
Description: Ventilation strategies with 4 kinds of ventilator mode since weaning cardiopulmonary bypass (CPB), Four group were control EtCO2 between 35～45mmHg by adjusting respiratory rate, EIT Measurements were performed under supine position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilation mode setting
Description: Ventilation strategies with 4 kinds of ventilator mode since weaning cardiopulmonary bypass (CPB), Four group were control EtCO2 between 35～45mmHg by adjusting respiratory rate, EIT Measurements were performed under supine position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilation mode setting
Description: Ventilation strategies with 4 kinds of ventilator mode since weaning cardiopulmonary bypass (CPB), Four group were control EtCO2 between 35～45mmHg by adjusting respiratory rate, EIT Measurements were performed under supine position
Study: NCT00495326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine based therapy
Description: * Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg~* Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz based therapy
Description: Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
Description: * Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~* Continuation phase: 4 months daily H(RMP).~* Patients with meningitis will receive Streptomycin instead of E during intensive phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
Description: * Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~* Continuation phase: 4 months daily H(RMP).~* Patients with meningitis will receive Streptomycin instead of E during intensive phase.
Study: NCT02578550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)
Description: A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)
Description: A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir alafenamide FDC
Description: A single tablet containing FTC 200 mg and TAF 10 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir alafenamide FDC
Description: A single tablet containing FTC 200 mg and TAF 10 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: A single tablet containing darunavir 800 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: A single tablet containing darunavir 800 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: A single table containing cobistat 150 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: A single table containing cobistat 150 mg will be administered.
Study: NCT00519337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic acid
Description: Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, 4 capsules the night before surgery followed by 1 capsule B.I.D. for 4 postoperative days
Study: NCT03673826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 9 cycles 20/36mg/m2 days 1,2,8,9,15,16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21
Study: NCT05138978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer
Description: Toothpaste

Intervention type: DRUG
Group type: OTHER
Intervention: Colgate Cavity Protection
Description: Toothpaste
Study: NCT04435899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Multi-modal exercise protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Multi-modal exercise protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Multi-modal exercise protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Multi-modal exercise protocol
Study: NCT02624882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive rapid GAS test
Description: If TDR positive, the child will be treated with antibiotics alone:~* Amoxicillin 50mg / kg / day in 2 divided doses for 10 days (maximum dose 3 g / day in 2 divided doses) Or if allergic to penicillins and in the absence of cross-known allergy to cephalosporins~* Cefpodoxime 8mg / kg / day in 2 divided doses for 10 days (maximum dose 400mg / day in 2 divided doses) J10 A control visit will review all the children included in the study. If the surgeon deems it necessary, the patient will be reviewed in consultation up to three months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Negative rapid GAS test
Description: Usual care
Study: NCT01935986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01775787

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor
Description: Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco \& Menthol Flavor for 7-10 days or Tobacco \& Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor
Description: Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco \& Menthol Flavor for 7-10 days or Tobacco \& Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days
Study: NCT03215875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fed- 60mg ER Torsemide
Description: 60mg ER Torsemide will be given after high fat, high-calorie meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasting- 60mg ER Torsemide
Description: 60mg ER Torsemide will be given after overnight fasting
Study: NCT03003702

Intervention type: DEVICE
Group type: OTHER
Intervention: Nonin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonin
Study: NCT03004768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral solution dose of 24 mg \[14C\] BMS-986165 containing approximately 100 micro Ci of TRA
Study: NCT01903577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Task Performance
Description: Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Task Performance
Description: Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Task Performance
Description: Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic Task Performance
Description: Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic Task Performance
Description: Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic Task Performance
Description: Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.
Study: NCT04120428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic exercise training program
Description: The intervention will be performed in a pool in which the water surface line will remain in the imaginary line of the xiphoid process. Each season will last 50 minutes and will be divided in 3 phases as (1) warm-up (15 minutes), (2) main part (30 minutes) and (3) cool-down (5 minutes).
Study: NCT04027764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Combined With S1 and Albumin Paclitaxel
Description: Toripalimab 240 mg ，every 2-3 weeks S1：80-120mg，bid；oral，d1-14； Albumin Paclitaxel：120mg/m2，D 1 \\8
Study: NCT03211559

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: clinical pilates on mat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: clinical pilates on mat
Study: NCT03879356

Intervention type: DRUG
Group type: OTHER
Intervention: N-acetyl cysteine
Description: effect of N-acetyl cysteine in Aluminum phosphide poisoning patients
Study: NCT01208064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Study: NCT02575378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronimic chemotherapy plus Chinese Traditional Medicine
Description: Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine

Intervention type: DRUG
Group type: OTHER
Intervention: Metronimic chemotherapy
Description: Capecitabine 300mg/m2, twice a day, everyday